- Home
- LSBK vs ACET Comparison
LSBK vs ACET Comparison
Compare LSBK & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSBK
- ACET
- Stock Information
- Founded
- LSBK 1891
- ACET 1947
- Country
- LSBK United States
- ACET United States
- Employees
- LSBK N/A
- ACET N/A
- Industry
- LSBK Savings Institutions
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- LSBK Finance
- ACET Health Care
- Exchange
- LSBK Nasdaq
- ACET Nasdaq
- Market Cap
- LSBK N/A
- ACET 44.4M
- IPO Year
- LSBK 2006
- ACET N/A
- Fundamental
- Price
- LSBK $15.48
- ACET $0.59
- Analyst Decision
- LSBK
- ACET Buy
- Analyst Count
- LSBK 0
- ACET 6
- Target Price
- LSBK N/A
- ACET $6.00
- AVG Volume (30 Days)
- LSBK 6.4K
- ACET 509.0K
- Earning Date
- LSBK 05-06-2025
- ACET 05-13-2025
- Dividend Yield
- LSBK 4.71%
- ACET N/A
- EPS Growth
- LSBK 6.97
- ACET N/A
- EPS
- LSBK 0.88
- ACET N/A
- Revenue
- LSBK $25,846,000.00
- ACET N/A
- Revenue This Year
- LSBK N/A
- ACET N/A
- Revenue Next Year
- LSBK N/A
- ACET N/A
- P/E Ratio
- LSBK $17.42
- ACET N/A
- Revenue Growth
- LSBK N/A
- ACET N/A
- 52 Week Low
- LSBK $11.00
- ACET $0.45
- 52 Week High
- LSBK $16.95
- ACET $1.87
- Technical
- Relative Strength Index (RSI)
- LSBK 58.47
- ACET 42.27
- Support Level
- LSBK $14.20
- ACET $0.51
- Resistance Level
- LSBK $14.69
- ACET $0.62
- Average True Range (ATR)
- LSBK 0.31
- ACET 0.06
- MACD
- LSBK 0.14
- ACET 0.01
- Stochastic Oscillator
- LSBK 100.00
- ACET 63.38
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.